Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
ConclusionsOur results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.
Source: PLoS Medicine - Category: Internal Medicine Authors: Jane J. Kim Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Cervical Cancer Vaccine | Genital Warts | History of Medicine | Human Papillomavirus (HPV) | Internal Medicine | Oropharyngeal Cancer | Penile Cancer | Study | USA Health | Vaccines | Warts | Women